Tony Hixson

AI Summary

→ WHAT IT COVERS Tony Hixson, Chief Business Officer at Cancer Research Horizons, explains how Cancer Research UK's commercial subsidiary bridges early-stage oncology research to market through spinouts, licensing, and the See Further initiative — a £50M multi-charity joint venture targeting childhood cancer medicines neglected by pharmaceutical companies. → KEY INSIGHTS - **Pediatric cancer drug gap:** Only nine cancer drugs received exclusive pediatric approval from the EMA and FDA over the last twenty years, compared to sixty adult indications approved in 2024 alone. Researchers and funders targeting this space should prioritize biology native to child development — fusion proteins, transcription factors — rather than adapting adult mechanisms that rarely translate directly. - **See Further joint venture model:** Cancer Research Horizons, Astellas, LifeArc, and Great Ormond Street Hospital's charity pooled £50M into See Further, a structure covering both child-first and child-only programs. Current programs target Ewing's sarcoma via small molecule and multiple childhood cancers via off-the-shelf cell therapy, with additional programs expected before end of 2024. - **Early investor engagement reduces wasted experiments:** Engaging venture capital and industry partners at the earliest possible stage — before finalizing experimental plans — produces targeted feedback on missing data points. Waiting until results are complete before approaching investors risks being sent back to repeat costly experiments that could have been designed correctly from the outset. - **UK proof-of-concept funding deficit:** Stanford University deploys over $20M annually in proof-of-concept funding; Leuven University in Flanders allocates £20–30M for a single region. The UK government's equivalent budget totals £8M distributed across all universities nationally — a structural gap that leaves viable early-stage assets undeveloped and represents the single largest bottleneck in UK translational research. - **Impact metrics over revenue targets:** Cancer Research Horizons tracks 28 million patient doses of drugs it helped advance and over 1.5 million quality-adjusted life years added, with no internal revenue targets. Organizations seeking charity or public-sector research partnerships should align proposals around measurable patient outcomes rather than commercial return projections to match this funding culture. → NOTABLE MOMENT Hixson notes that pharmaceutical companies acting rationally — prioritizing shareholder returns — will structurally avoid rare pediatric cancers with no adult follow-on indication. This means some childhood cancer medicines may need to reach patients entirely without industry involvement, requiring entirely new funding and development models. 💼 SPONSORS None detected 🏷️ Pediatric Oncology, Cancer Research UK, Drug Discovery, Translational Medicine, Biotech Spinouts